Paul Baughman
Obesity Medicine · Harrisburg, PANPI 1902861230
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 260 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 19 manufacturers reported payments, led by Novo Nordisk at 47.0% of the total.
Across 260 payments — averaging $13.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$2K
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$322
- Takeda Pharmaceuticals U.S.A., Inc.$291
- Lilly USA, LLC$246
- Jazz Pharmaceuticals Inc.$222
- Daiichi Sankyo Inc.$175
- plus $556 from 13 others
What the payments were for
- Food & beverage$3,420100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 143 | $1,607 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 19 | $322 |
| Takeda Pharmaceuticals U.S.A., Inc. | 23 | $291 |
| Lilly USA, LLC | 14 | $246 |
| Jazz Pharmaceuticals Inc. | 15 | $222 |
| Daiichi Sankyo Inc. | 15 | $175 |
| Currax Pharmaceuticals LLC | 6 | $85 |
| Corcept Therapeutics | 4 | $73 |
| AstraZeneca | 4 | $67 |
| Eisai Inc. | 2 | $59 |
| Intra-sana Laboratories | 2 | $57 |
| Optinose US, Inc. | 2 | $39 |
| Ironshore Pharmaceuticals Inc. | 2 | $39 |
| Neos Therapeutics, LP | 2 | $31 |
| Xeris Pharmaceuticals, Inc. | 2 | $31 |
| Merck | 2 | $24 |
| Inspire Medical Systems, Inc. | 1 | $19 |
| Rhythm Pharmaceuticals, Inc. | 1 | $17 |
| Sanofi-aventis U.S. LLC | 1 | $14 |
How this compares
Too few obesity medicine providers in Pennsylvaniato place this figure against a meaningful peer group, so we don't.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Naltrexone Hcl | 13 | $546 |
| Bupropion Hcl SrBupropion Hcl | 13 | $152 |
Paid to pharmacies, not to this prescriber.
Other obesity medicine in Harrisburg
- Karel KeiterHarrisburg$59
- Margarita McDonaldAmbler$111K
- Sunil DanielAllentown$9K
- Joseph McPheeLancaster$9K
- Rena LambertAllentown$2K
- Robin SchroederAllentown$954
- Lawrence WiegerLancaster$678
- Charles SeltzerPhiladelphia$623
- Adarsh GuptaWest Norriton$529
- Kia WestAllentown$310
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.